Format

Send to

Choose Destination
J Rheumatol. 1992 Sep;19(9):1348-52.

Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis.

Author information

1
Rheumatology Unit, United Medical School, Guy's Hospital, London, UK.

Abstract

Murine monoclonal antibody (Mab) therapy in patients with rheumatoid arthritis (RA) produces an antimouse immunoglobulin response by the recipient. We studied a chimeric (human/mouse) CD7 Mab, in a dose ranging tolerability study in 10 patients with RA. Modest improvements in disease activity occurred with frequent acute adverse effects of malaise, fever and nausea. After treatment, peripheral blood T lymphocyte numbers fell by 50% and CD7 expression fell by 97% for less than 7 days. Our study demonstrates chimeric Mab function in vivo and illustrates the influence of antibody isotype and patient characteristics on adverse effects.

PMID:
1279168
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center